# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-25-050391
Filing Date
2025-04-03
Accepted
2025-04-03 16:10:44
Documents
21
Period of Report
2025-06-05

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | crsp-20250403.htm iXBRL | PRE 14A | 3010774
2 | GRAPHIC | img170269993_0.jpg | GRAPHIC | 87689
3 | GRAPHIC | img170269993_1.jpg | GRAPHIC | 66170
4 | GRAPHIC | img170269993_2.jpg | GRAPHIC | 640791
5 | GRAPHIC | img170269993_3.jpg | GRAPHIC | 544472
6 | GRAPHIC | img170269993_4.jpg | GRAPHIC | 573797
7 | GRAPHIC | img170269993_5.jpg | GRAPHIC | 1000094
8 | GRAPHIC | img170269993_6.jpg | GRAPHIC | 1419671
| Complete submission text file | 0000950170-25-050391.txt |  | 15441564

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
9 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | crsp-20250403.xsd | EX-101.SCH | 7548
23 | EXTRACTED XBRL INSTANCE DOCUMENT | crsp-20250403_htm.xml | XML | 610374

Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37923 | Film No.: 25809520
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)